Jackson Thornton Wealth Management LLC Invests $584,000 in Medpace Holdings, Inc. $MEDP

Jackson Thornton Wealth Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,099 shares of the company’s stock, valued at approximately $584,000.

Other hedge funds have also added to or reduced their stakes in the company. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Mawer Investment Management Ltd. boosted its holdings in Medpace by 17.4% in the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after acquiring an additional 121,213 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Medpace by 15.1% during the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after acquiring an additional 81,637 shares during the last quarter. TD Asset Management Inc increased its stake in shares of Medpace by 15.6% during the 2nd quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after purchasing an additional 61,764 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock valued at $139,740,000 after purchasing an additional 45,435 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares in the company, valued at $470,787,603.56. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, President Jesse J. Geiger sold 21,503 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is currently owned by corporate insiders.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $596.63 on Tuesday. The stock has a fifty day moving average price of $582.94 and a 200 day moving average price of $514.69. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The company has a market cap of $16.81 billion, a PE ratio of 41.62, a P/E/G ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the company earned $3.01 earnings per share. Medpace’s quarterly revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MEDP shares. Mizuho set a $660.00 price target on shares of Medpace in a report on Friday, January 9th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Robert W. Baird set a $613.00 price target on Medpace in a report on Friday, October 24th. TD Cowen boosted their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Finally, Barclays lifted their target price on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.